动脉粥样硬化中胆固醇逆向转运的研究进展  

Advances on Reverse Cholesterol Transport in Atherosclerosis

作　　者：王嘉宾 肖云飞 吴珺 韩梅 WANG Jiabin;XIAO Yunfei;WU Jun;HAN Mei(Key Laboratory of Medical Biotechnology of Hebei Province,Department of Biochemistry and Molecular Biology,College of Basic Medicine,Hebei Medical University,Shijiazhuang 050017,China)

机构地区：[1]河北医科大学基础医学院,生物化学与分子生物学教研室河北省医学生物技术重点实验室,石家庄050017

出　　处：《中国细胞生物学学报》2020年第9期1662-1668,共7页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:91739301、91849102)资助的课题。

摘　　要：胆固醇逆向转运(reverse cholesterol transport,RCT)是指胆固醇从外周组织细胞流出,通过高密度脂蛋白转运至肝脏进行代谢转变的过程,是维持细胞脂质稳态的重要机制。RCT相关基因的功能障碍是动脉粥样硬化脂质沉积、慢性炎症和泡沫细胞形成的主要病因,已成为抗动脉粥样硬化的主要靶点。该文就近年来关于胆固醇逆向转运的调节和定量分析在动脉粥样硬化中的最新研究进展作一综述。RCT(reverse cholesterol transport)is a multi-step process,by which peripheral cell cholesterol can be returned to the liver for catabolism by HDL(high density lipoprotein)via the plasma compartment,and it is an essential mechanism to maintain the lipid homeostasis of peripheral tissue cells.The dysfunction of individual genes relavant to RCT may result in lipid deposition,chronic inflammation and foam cell formation in atherosclerosis,and modulation of RCT serves as a valuable therapeutic strategy for atherosclerotic diseases.This article reviews the latest advances in study on regulation and quantification of RCT in atherosclerosis.

关 键 词：胆固醇逆向转运 巨噬细胞 淋巴系统 动脉粥样硬化 

分 类 号：R543.5[医药卫生—心血管疾病]